Download
fvets-08-702018.pdf 736,60KB
WeightNameValue
1000 Titel
  • An Accessible Alternative to Melarsomine: “Moxi-Doxy” for Treatment of Adult Heartworm Infection in Dogs
1000 Autor/in
  1. Jacobson, Linda S. |
  2. DiGangi, Brian A. |
1000 Verlag
  • Frontiers Media S.A.
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-07-27
1000 Erschienen in
1000 Quellenangabe
  • 8:702018
1000 Copyrightjahr
  • 2021
1000 Embargo
  • 2022-01-29
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.3389/fvets.2021.702018 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353148/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Abstract/Summary
  • <jats:p>Canine heartworm infection, caused by the filarial parasite <jats:italic>Dirofilaria immitis</jats:italic>, represents a serious and expanding animal welfare concern that is expected to increase due to the effects of climate change and the COVID-19 pandemic. A body of evidence has emerged to support the use of a non-arsenical adulticide treatment protocol, using moxidectin and doxycycline to kill adult heartworms over a prolonged period. While a three-dose protocol using the arsenical drug melarsomine is currently the safest and most effective treatment for heartworm infection, this drug is not available in some countries and is inaccessible for many owners and animal shelters. Moxidectin-doxycycline (moxi-doxy) provides a viable alternative to no treatment at all, in cases where arsenical treatment is not possible. Based on current evidence, the most effective non-arsenical treatment regimen is doxycycline 10 mg/kg PO q 12 or 24 h for 28 days, combined with topical moxidectin at label dose. Moxidectin is repeated monthly until no antigen detected (NAD) status is confirmed. Sustained release injectable moxidectin, in combination with doxycycline, may provide an alternative in remote regions or in settings where significant compliance or accessibility concerns exist, but more studies are needed. In moxi-doxy protocols, doxycycline should be repeated annually until NAD. This review summarizes the safety and efficacy of moxi-doxy, addresses controversies surrounding this treatment approach, and provides detailed recommendations for treatment regimens and post-treatment testing.</jats:p>
1000 Sacherschließung
lokal Veterinary Science
lokal accessible veterinary care
lokal adulticide treatment
lokal slow kill
lokal heartworm
lokal melarsomine
lokal doxycycline
lokal moxidectin
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/SmFjb2Jzb24sIExpbmRhIFMu|https://frl.publisso.de/adhoc/uri/RGlHYW5naSwgQnJpYW4gQS4=
1000 Hinweis
  • DeepGreen-ID: aa73bc4132894aa7a5e7c319eba06287 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6477021.rdf
1000 Erstellt am 2024-05-17T10:41:54.627+0200
1000 Erstellt von 322
1000 beschreibt frl:6477021
1000 Zuletzt bearbeitet 2024-05-17T14:06:16.230+0200
1000 Objekt bearb. Fri May 17 14:06:16 CEST 2024
1000 Vgl. frl:6477021
1000 Oai Id
  1. oai:frl.publisso.de:frl:6477021 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source